BioCentury | May 1, 2020
Product Development

April 30 Quick Takes: Pfizer to co-develop Valneva’s Lyme disease vaccine; plus Aravive-WuXi Biologics, Siga-BARDA, Pear, Capricor

...an Fc fusion protein that targets the AXL/GAS6 pathway. BARDA exercises $101.3M in options for Siga’s...
...of options to procure for the national stockpile TPOXX tecovirimat, a smallpox therapy from Siga Technologies Inc. (NASDAQ:SIGA...
...A BioCentury Staff VLA15, VLA15-101 Oral TPOXX, oral tecovirimat (oral ST-246, oral Arestvyr, SIGA-246) reSET reSET-O CAP-1002 Valneva SE Pfizer Inc. Aravive Inc. WuXi Biologics Inc. Siga Technologies Inc. Capricor...
BioCentury | Mar 18, 2019
Company News

Biohaven spends $105M for faster review of oral CGRP inhibitor

...issued in 2009, prices have ranged from $67.5 million to $350 million (see "Lilly Buys Siga's...
BioCentury | Jan 5, 2019
Finance

Ready to launch

The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record year...
BioCentury | Nov 2, 2018
Company News

Lilly buys Siga's Priority Review voucher gained via smallpox approval

...NYSE:LLY) acquired a Priority Review voucher from Siga Technologies Inc. (NASDAQ:SIGA) for $80 million. The voucher, which Siga...
...oral small molecule antiviral, is the first drug FDA has approved to treat smallpox (see "Siga...
...associated with threats and emerging infectious diseases.” Siga was up $0.02 to $4.85 Nov.1. Siga Technologies Inc. (NASDAQ:SIGA...
BioCentury | Nov 1, 2018
Company News

Lilly buys Siga's Priority Review voucher gained via smallpox approval

...NYSE:LLY) acquired a Priority Review voucher from Siga Technologies Inc. (NASDAQ:SIGA) for $80 million. The voucher, which Siga...
...oral small molecule antiviral, is the first drug FDA has approved to treat smallpox (see "Siga...
...$0.02 to $4.85 Thursday. Paul Bonanos Oral TPOXX, oral tecovirimat (oral ST-246, oral Arestvyr, SIGA-246) Eli Lilly and Co. Siga Technologies Inc....
BioCentury | Oct 6, 2018
Finance

Large cap comeback

...Takhzyro lanadelumab-flyo to prevent attacks of hereditary angioedema in patients ages 12 and older Siga Technologies Inc. (NASDAQ:SIGA...
BioCentury | Sep 21, 2018
Company News

Siga signs BARDA contract for smallpox drug worth up to $629M

...Siga Technologies Inc. (NASDAQ:SIGA) signed a contract with HHS's Biomedical Advanced Research and Development Authority (BARDA...
...funds for vendor-managed storage and post-marketing activities. This is Siga's third BARDA contract for TPOXX. Siga...
...confirm dosing. The company received the first Material Threat Medical Countermeasure Priority Review voucher. Siga Technologies Inc. (NASDAQ:SIGA...
BioCentury | Jul 20, 2018
Clinical News

Siga gets Priority Review voucher for first approved smallpox drug

...Siga Technologies Inc. (NASDAQ:SIGA) became the first company to gain FDA approval for a smallpox drug...
...for a smallpox drug and received the first Material Threat Medical Countermeasure Priority Review voucher. Siga...
...animal studies and human clinical studies are conducted to determine safety and confirm dosing. Siga Technologies Inc. (NASDAQ:SIGA...
BioCentury | Jul 13, 2018
Company News

Siga gets Priority Review voucher for first approved smallpox drug

...Siga Technologies Inc. (NASDAQ:SIGA) became the first company to gain FDA approval for a smallpox drug...
...for a smallpox drug and received the first Material Threat Medical Countermeasure Priority Review voucher. Siga...
...smallpox ahead of the small molecule antiviral's Aug. 8 PDUFA date. CEO Phil Gomez said Siga...
BioCentury | Jun 30, 2018
Finance

Eyes on launches

...date 12/21/18 Sienna Biopharmaceuticals Inc. (NASDAQ:SNNA) SNA-001 Acne vulgaris Pivotal trial data 3Q18; 4Q18 Siga Technologies Inc. (NASDAQ:SIGA...
Items per page:
1 - 10 of 193
BioCentury | May 1, 2020
Product Development

April 30 Quick Takes: Pfizer to co-develop Valneva’s Lyme disease vaccine; plus Aravive-WuXi Biologics, Siga-BARDA, Pear, Capricor

...an Fc fusion protein that targets the AXL/GAS6 pathway. BARDA exercises $101.3M in options for Siga’s...
...of options to procure for the national stockpile TPOXX tecovirimat, a smallpox therapy from Siga Technologies Inc. (NASDAQ:SIGA...
...A BioCentury Staff VLA15, VLA15-101 Oral TPOXX, oral tecovirimat (oral ST-246, oral Arestvyr, SIGA-246) reSET reSET-O CAP-1002 Valneva SE Pfizer Inc. Aravive Inc. WuXi Biologics Inc. Siga Technologies Inc. Capricor...
BioCentury | Mar 18, 2019
Company News

Biohaven spends $105M for faster review of oral CGRP inhibitor

...issued in 2009, prices have ranged from $67.5 million to $350 million (see "Lilly Buys Siga's...
BioCentury | Jan 5, 2019
Finance

Ready to launch

The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record year...
BioCentury | Nov 2, 2018
Company News

Lilly buys Siga's Priority Review voucher gained via smallpox approval

...NYSE:LLY) acquired a Priority Review voucher from Siga Technologies Inc. (NASDAQ:SIGA) for $80 million. The voucher, which Siga...
...oral small molecule antiviral, is the first drug FDA has approved to treat smallpox (see "Siga...
...associated with threats and emerging infectious diseases.” Siga was up $0.02 to $4.85 Nov.1. Siga Technologies Inc. (NASDAQ:SIGA...
BioCentury | Nov 1, 2018
Company News

Lilly buys Siga's Priority Review voucher gained via smallpox approval

...NYSE:LLY) acquired a Priority Review voucher from Siga Technologies Inc. (NASDAQ:SIGA) for $80 million. The voucher, which Siga...
...oral small molecule antiviral, is the first drug FDA has approved to treat smallpox (see "Siga...
...$0.02 to $4.85 Thursday. Paul Bonanos Oral TPOXX, oral tecovirimat (oral ST-246, oral Arestvyr, SIGA-246) Eli Lilly and Co. Siga Technologies Inc....
BioCentury | Oct 6, 2018
Finance

Large cap comeback

...Takhzyro lanadelumab-flyo to prevent attacks of hereditary angioedema in patients ages 12 and older Siga Technologies Inc. (NASDAQ:SIGA...
BioCentury | Sep 21, 2018
Company News

Siga signs BARDA contract for smallpox drug worth up to $629M

...Siga Technologies Inc. (NASDAQ:SIGA) signed a contract with HHS's Biomedical Advanced Research and Development Authority (BARDA...
...funds for vendor-managed storage and post-marketing activities. This is Siga's third BARDA contract for TPOXX. Siga...
...confirm dosing. The company received the first Material Threat Medical Countermeasure Priority Review voucher. Siga Technologies Inc. (NASDAQ:SIGA...
BioCentury | Jul 20, 2018
Clinical News

Siga gets Priority Review voucher for first approved smallpox drug

...Siga Technologies Inc. (NASDAQ:SIGA) became the first company to gain FDA approval for a smallpox drug...
...for a smallpox drug and received the first Material Threat Medical Countermeasure Priority Review voucher. Siga...
...animal studies and human clinical studies are conducted to determine safety and confirm dosing. Siga Technologies Inc. (NASDAQ:SIGA...
BioCentury | Jul 13, 2018
Company News

Siga gets Priority Review voucher for first approved smallpox drug

...Siga Technologies Inc. (NASDAQ:SIGA) became the first company to gain FDA approval for a smallpox drug...
...for a smallpox drug and received the first Material Threat Medical Countermeasure Priority Review voucher. Siga...
...smallpox ahead of the small molecule antiviral's Aug. 8 PDUFA date. CEO Phil Gomez said Siga...
BioCentury | Jun 30, 2018
Finance

Eyes on launches

...date 12/21/18 Sienna Biopharmaceuticals Inc. (NASDAQ:SNNA) SNA-001 Acne vulgaris Pivotal trial data 3Q18; 4Q18 Siga Technologies Inc. (NASDAQ:SIGA...
Items per page:
1 - 10 of 193